FDA Approved: NEURONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)

View source ↗

Summary

The FDA approved a supplemental application for Neurontin (gabapentin) submitted by Parke-Davis Division of Pfizer Inc, indicating a change to its labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Neuropathic Pain
• Postherpetic Neuralgia

Drugs mentioned

• NEURONTIN (gabapentin)

Snippet

SUPPL AP for NEURONTIN (GABAPENTIN)